Arching deep brain stimulation in dystonia types

J Neural Transm (Vienna). 2021 Apr;128(4):539-547. doi: 10.1007/s00702-021-02304-4. Epub 2021 Mar 19.

Abstract

Although medical treatment including botulinum toxic injection is the first-line treatment for dystonia, response is insufficient in many patients. In these patients, deep brain stimulation (DBS) can provide significant clinical improvement. Mounting evidence indicates that DBS is an effective and safe treatment for dystonia, especially for idiopathic and inherited isolated generalized/segmental dystonia, including DYT-TOR1A. Other inherited dystonia and acquired dystonia also respond to DBS to varying degrees. For Meige syndrome (craniofacial dystonia), other focal dystonia, and some rare inherited dystonia, further evidences are still needed to evaluate the role of DBS. Because short disease duration at DBS surgery and absence of fixed musculoskeletal deformity are associated with better outcome, DBS should be considered as early as possible when indicated after careful evaluation including genetic work-up. This review will focus on the factors to be considered in DBS for patients with dystonia and the outcome of DBS in the different types of dystonia.

Keywords: Deep brain stimulation (DBS); Dystonia; Inherited; Pallidal; Subthalamic.

Publication types

  • Review

MeSH terms

  • Deep Brain Stimulation*
  • Dystonia* / therapy
  • Dystonic Disorders* / therapy
  • Globus Pallidus
  • Humans
  • Molecular Chaperones
  • Treatment Outcome

Substances

  • Molecular Chaperones
  • TOR1A protein, human